(0.10%) 5 522.25 points
(0.13%) 39 897 points
(0.20%) 19 791 points
(-0.04%) $81.60
(0.53%) $2.83
(-0.29%) $2 337.70
(0.14%) $29.57
(0.32%) $1 005.00
(-0.01%) $0.931
(-0.04%) $10.53
(-0.03%) $0.788
(-0.85%) $87.25
-3.47% $ 0.885
Live Chart Being Loaded With Signals
Progenity, Inc., a biotechnology company, provides develops and commercializes molecular testing products in the United States. The company develops targeted oral delivery of biotherapeutics, including PGN-600, an orally delivered liquid formulation of tofacitinib for the treatment of ulcerative colitis; and PGN-001, an orally delivered variant of adalimumab for the treatment of ulcerative colitis...
Stats | |
---|---|
Dzisiejszy wolumen | 2.78M |
Średni wolumen | 6.37M |
Kapitalizacja rynkowa | 8.18M |
EPS | $-0.140 ( Q1 | 2024-05-15 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-0.257 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.131 (14.81%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2022-04-15 | Desparbes Eric | Buy | 231 693 | Common Stock |
2022-04-15 | Neumann Clarke | Buy | 184 843 | Common Stock |
INSIDER POWER |
---|
0.00 |
Last 2 transactions |
Buy: 416 536 | Sell: 0 |
Wolumen Korelacja
Progenity, Inc. Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
ENNV | 0.946 |
TVACW | 0.926 |
SRNGW | 0.916 |
HJLIW | 0.904 |
AZRX | 0.902 |
LSAQ | 0.887 |
XPDI | 0.88 |
OBLN | 0.878 |
SRNG | 0.867 |
TCDA | 0.856 |
10 Najbardziej negatywne korelacje | |
---|---|
FTIV | -0.909 |
SCOB | -0.881 |
MSAC | -0.874 |
BCOR | -0.861 |
LGACU | -0.859 |
ITQ | -0.842 |
CTAQ | -0.831 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Progenity, Inc. Korelacja - Waluta/Towar
Progenity, Inc. Finanse
Annual | 2023 |
Przychody: | $4 000.00 |
Zysk brutto: | $-551 000 (-13 775.00 %) |
EPS: | $-7.87 |
FY | 2023 |
Przychody: | $4 000.00 |
Zysk brutto: | $-551 000 (-13 775.00 %) |
EPS: | $-7.87 |
FY | 2022 |
Przychody: | $305 000 |
Zysk brutto: | $-602 000 (-197.38 %) |
EPS: | $-6.40 |
FY | 2021 |
Przychody: | $1.25M |
Zysk brutto: | $1.25M (100.00 %) |
EPS: | $-9.18 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Progenity, Inc.
Progenity, Inc., a biotechnology company, provides develops and commercializes molecular testing products in the United States. The company develops targeted oral delivery of biotherapeutics, including PGN-600, an orally delivered liquid formulation of tofacitinib for the treatment of ulcerative colitis; and PGN-001, an orally delivered variant of adalimumab for the treatment of ulcerative colitis. It also develops systemic oral delivery of biotherapeutics, which include PGN-OB, a combination product of a variant of adalimumab and the Oral Biotherapeutics Delivery System (OBDM) for the treatment of inflammatory conditions; and PGN-OB2, a combination product of a GLP-1 receptor agonist and the OBDS for the treatment of Type 2 diabetes. In addition, the company develops Recoverable Sampling System, an ingestible smart capsule designed to autonomously identify locations in the GI tract, collect, and preserve a sample for analysis; and PIL Dx, an ingestible smart capsule designed to sample, measure, and transmit results. It has partnership agreement with Ionis Pharmaceuticals to evaluate the OBDS for delivery of antisense oligonucleotides. The company was formerly known as Ascendant MDX, Inc. and changed its name to Progenity, Inc. in November 2013. The company was founded in 2010 and is headquartered in San Diego, California.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej